GP-39 Antibody (E-10): sc-393476

GP-39 Antibody (E-10) is a mouse monoclonal IgG1 antibody that detects human cartilage glycoprotein 39 (GP-39) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GP-39, also known as YKL-40, is a glycoprotein secreted primarily by articular chondrocytes, synoviocytes, and macrophages, playing a crucial role in inflammatory response and tissue remodeling. Elevated levels of GP-39 in serum and synovial fluid are associated with inflammatory diseases, particularly rheumatoid arthritis, where GP-39 levels correlate with the extent of joint destruction. GP-39 is predominantly expressed in articular chondrocytes and synovial cells, with additional expression noted in the liver, while remaining undetectable in muscle tissues, lung, pancreas, mononuclear cells, and fibroblasts. As a candidate autoantigen in rheumatoid arthritis, GP-39 plays an important role in cellular adaptation to environmental changes. Anti-GP-39 antibody (E-10) serves as an essential tool for researchers investigating GP-39′s role in various pathological conditions, providing insights into inflammatory processes and potential therapeutic targets.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GP-39 Antibody (E-10) References:

1. Analysis of chondrex (YKL-40, HC gp-39) in the cerebrospinal fluid of patients with spine disease.  |  Tsuji, T., et al. 2002. Spine (Phila Pa 1976). 27: 732-5. PMID: 11923666
2. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways.  |  Recklies, AD., et al. 2002. Biochem J. 365: 119-26. PMID: 12071845
3. Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint.  |  van Lierop, MJ., et al. 2007. Arthritis Rheum. 56: 2150-9. PMID: 17599744
4. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.  |  Foy, TM., et al. 1994. J Exp Med. 180: 157-63. PMID: 7516405
5. The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease.  |  Durie, FH., et al. 1994. Res Immunol. 145: 200-5; discussion 244-9. PMID: 7527576
6. The expansive role of CD40 and its ligand, gp39, in immunity.  |  Foy, TM., et al. 1994. Semin Immunol. 6: 259-66. PMID: 7532456
7. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.  |  Durie, FH., et al. 1993. Science. 261: 1328-30. PMID: 7689748
8. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.  |  Van den Eertwegh, AJ., et al. 1993. J Exp Med. 178: 1555-65. PMID: 7693849
9. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.  |  Larsen, CP., et al. 1996. Transplantation. 61: 4-9. PMID: 8560571
10. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.  |  Clegg, CH., et al. 1997. Int Immunol. 9: 1111-22. PMID: 9263008

The preferred GP-39 antibody is GP-39 Antibody (E-11): sc-376910.